PM Narendra Modi has chaired high-level meeting to review the planning and preparations for vaccination against Covid-19, as and when the vaccine is available.
Prime Minister noted that vaccination of India’s vast and diverse population will need to factor in issuesincluding those related to management of medical supply chains, prioritization of at-risk populations, coordination between different agencies involved in the process, as well as the role of private sector and civil society in this national endeavour.
Prime Minister enunciated four guiding principles that will form the foundation of this national effort: first, that vulnerable groups should be identified and prioritized for early vaccination, for example doctors, nurses, healthcare workers, non-medical frontline corona warriors, and vulnerable people among the general population; second, that vaccination of “anyone, anywhere” should take place,iewithout imposition of any domicile related restrictions for getting the vaccine; third, that vaccination must be affordable and universal – no person should be left behind; and fourth, that the entire process from production to vaccination should be monitored and supported in real time with the use of technology.
PM directed officials to evaluate in a broad manner available technology options that can form the backbone of the national endeavor to vaccinate all in the most efficient and timely manner.
Prime Minister directed that detailed planning for such large scale vaccination should be undertaken immediately.
The current status of vaccine development efforts were also reviewed at the meeting. Prime Minister highlighted India’s commitment to play an enabling role in the vaccination efforts against Covid-19.
Good News on card
PM reviewed meeting when India’s first coronavirus vaccine COVAXIN developed by Hyderabad-based Bharat Biotech has got approval from the Drug Controller General of India (DCGI) to start human clinical trials. The company said it is pleased to announce its 3 COVID-19 vaccines in collaboration with the University of WISCONSIN, ICMR, and Thomas Jefferson University. Coronavirus vaccine –COVAXIN– is India’s first indigenous inactivated vaccine for highly infectious and deadly disease COVID-19.
The DGCI, CDSCO (Central Drugs Standard Control Organisation), and Ministry of Health and Family Welfare granted permission to initiate Phase I and II human clinical trials after the company submitted results generated from pre-clinical studies, demonstrating safety and immune response